Active	Status	Sponsor type	Region	Phase	Filter
19 Active 0 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Califano, Catello
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma	Withdrawn	2	150	Europe	R-DHAP, Pola-R-DHAP	Fondazione Italiana Linfomi - ETS, Roche Pharma AG	Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent	01/29	01/29
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients	Recruiting	1/2	122	Europe	Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine	Fondazione Italiana Linfomi - ETS, Roche Pharma AG	Relapsed or Refractory Hodgkin's Lymphoma	04/27	04/30
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -	Recruiting	N/A	190	Europe	acalabrutinib, Calquence	AstraZeneca, Yghea	Chronic Lymphocytic Leukemia	02/30	02/30
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice	Recruiting	N/A	1500	Europe	"novel" MAB (alone or in combination)	Fondazione Italiana Linfomi - ETS, Roche Pharma AG	Non-Hodgkin Lymphoma, B-cell	10/38	10/38